Development of real-time quantitative polymerase chain reaction assays to track treatment response in retinoid resistant acute promyelocytic leukemia

Development of real-time quantitative polymerase chain reaction assays to track treatment response in retinoid resistant acute promyelocytic leukemia

Molecular detection of minimal residual disease (MRD) has become established to assess remission status and guide therapy in patients with PML-RARA+ acute promyelocytic leukemia (APL). However, there are few data on tracking disease response in patients with rarer retinoid resistant subtypes of APL,...

Full description

Bibliographic Details
Main Authors: Jelena V Jovanovic, Kristian eRennie, Dominic eCulligan, Andrew ePeniket, Anne eLennard, Justin eHarrison, Paresh eVyas, David eGrimwade
Format: Article
Language:English
Published: Frontiers Media S.A. 2011-10-01
Series:Frontiers in Oncology
Subjects:
Acute Myeloid Leukemia
Minimal Residual Disease
Online Access:http://journal.frontiersin.org/Journal/10.3389/fonc.2011.00035/full

Internet

http://journal.frontiersin.org/Journal/10.3389/fonc.2011.00035/full

Similar Items